Relationship between parameters of adipokine and lipid profiles in patients with acute myocardial infarction and type 2 diabetes mellitus
DOI:
https://doi.org/10.32782/2415-8127.2022.65.3Keywords:
adipokines, biomarkers, lipids, comorbidity, metabolism.Abstract
Introduction. Nowadays, it becomes topical to search for methods of diagnosis and treatment for polymorbid patients. The importance of the study on pathophysiological mechanisms of acute myocardial infarction (AMI) in patients with type 2 diabetes mellitus (DM) has been shown. The aim of the study: to examine the relationship between adipokine and lipid profiles in AMI patients with the presence or absence of type 2 DM. Material and methods. The study was conducted over a period from September 1, 2018 to December 31, 2020. A total of 134 patients with ST-segment elevation AMI in the presence or absence of type 2 DM aged 58.97 ± 7.92 years hospitalized in the intensive care unit of Government Institution “L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine” and Kharkiv Railway Clinical Hospital No. 1 of the branch “Center of Healthcare” were enrolled in the study. Group 1 included 74 patients with AMI and type 2 DM aged 59.42 ± 7.66 years. Group 2 (comparison group) comprised 60 patients with AMI without type 2 DM aged 58.42 ± 8.25 years. The control group consisted of 20 otherwise healthy individuals. Serum concentrations of fatty acid-binding protein 4 (FABP4) and C1q/ TNF-related protein 3 (CTRP3) of patients were measured by enzyme-linked immunosorbent assay. Serum total cholesterol (TC) and highdensity lipoprotein (HDL) cholesterol were analyzed by peroxidase enzymatic method. Triglyceride (TG) levels were measured by enzymatic colorimetric method. The atherogenic index was calculated by the A.M. Klimov formula. The levels of very low-density lipoprotein (VLDL) cholesterol and low-density lipoprotein (LDL) cholesterol were estimated by the Friedewald formula. Results and discussion. The patients in Group 1 were found to have higher levels of serum TG in comparison with Group 2 patients (р<0.05). In groups 1 and 2, there was an upward tendency in the levels of TC and LDL (р ˃0.05), as well as a significant 4.04 and 2.92 times increase in VLDL, respectively, as compared to the control group (p<0.05). The serum levels of FABP4 were significantly increased, while CTRP3 levels were decreased in AMI patients compared to those in otherwise healthy individuals (р<0.05). In AMI patients with type 2 DM (group 1), an inverse correlation was found between FABP4 and VLDL (r = 0.502, p<0.05), TG (r = 0.596, p<0.001); between CTRP3 and TC (r = -0.507, p<0.05), LDL (r = -0.512, p<0.05). In patients with AMI (group 2), an inverse correlation was revealed between FABP4 and VLDL (r = 0.453, p = 0.006), TG (r = 0.439, p = 0.009); between CTRP3 and TC (r = -0.413, p = 0.001), LDL (r = -0.429, p = 0.01). Conclusions. The characteristics of changes in the FABP4 and CTRP3 serum levels are evidence of an adipokine metabolism imbalance in AMI with the presence or absence of type 2 DM, indicating a metabolic shift in this patient category. The relationship between lipid profile markers and FABP4 and CTRP3 may indicate the influence of the latter on lipid metabolism.
References
Cui J, Liu Y, Li Y, Xu F, Liu Y. Type 2 diabetes and myocardial infarction: recent clinical evidence and perspective. Frontiers in cardiovascular medicine. 2021; 8: 644189. DOI: https://doi.org/10.3389/fcvm.2021.644189.
Newsletter Top 10 causes of death in the world. WHO. December 9, 2020. URL: https://www.who.int/ru/news-room/factsheets/ detail/the-top-10-causes-of-death.
Pasiyeshvili L.M., Marchenko A.S., Zagrebelska A.V., Maly`k N.V., Karaya OV Rol ozhyrinnya ta osoblyvostey topografiyi zhyrovoyi tkanyny v perebigu tsukrovogo diabet u 2-go typu [The role of obesity and features of adipose tissue topography in the course of diabetes mellitus in type 2]. Zdobutky klinichnoyi i eksperymentalnoyi medytsyny. 2021; 4: 147–150. DOI: https:// doi.org/10.11603/1811-2471.2021.v.i4.12480 (in Ukrainian).
Tahir A., Martinez PJ., Ahmad F., Fisher-Hoch SP., McCormick J., Gay JL., et al. An evaluation of lipid profile and pro‑inflammatory cytokines as determinants of cardiovascular disease in those with diabetes: a study on a Mexican American cohort. Scientific reports. 2021; 11: 2435. DOI: https://doi.org/10.1038/s41598-021-81730-6.
Furuhashi M. Fatty acid-binding protein 4 in cardiovascular and metabolic diseases. Journal of atherosclerosis and thrombosis. 2019; 26(3): 216–232. DOI: https://doi.org/10.5551/jat.48710.
Si Y., Fan W, Sun L. A review of the relationship between CTRP family and coronary artery disease. Current atherosclerosis reports. 2020; 22(6): 22. DOI: https://doi.org/10.1007/s11883-020-00840-0.
Lee CH., Lui D., Lam K. Adipocyte fatty acid-binding protein, cardiovascular diseases and mortality. Frontiers in immunology. 2021; 12: 589206. DOI: https://doi.org/10.3389/fimmu.2021.589206.
Xiao Y., Xiao X., Xu A., Chen X., Tang W., Zhou Z. Circulating adipocyte fatty acid-binding protein levels predict the development of subclinical atherosclerosis in type 2 diabetes. Journal of diabetes and its complications. 2018; 32(12): 1100–1104. DOI: https://doi.org/10.1016/j.jdiacomp.2018.09.001.
Mourilhe-Rocha R., Bittencourt M.I. CTRP-3 levels in patients with stable coronary artery disease and paroxysmal atrial fibrillation: a new potential biomarker in cardiovascular diseases. Arquivos brasileiros de cardiologia. 2022; 118(1): 59–60. DOI: https://doi.org/10.36660/abc.20210940.
Yan Z., Cao X., Wang C., Liu S. Li Y, Lu G, et al. C1q/tumor necrosis factor-related protein-3 improves microvascular endothelial function in diabetes through the AMPK/eNOS/NO signaling pathway. Biochemical pharmacology. 2022;195: 114745. DOI: https://doi.org/10.1016/j.bcp.2021.114745.
Zhu H, Ding Y, Zhang Y, Ding X, Zhao J, Ouyang W, et al. CTRP3 induces an intermediate switch of CD14++CD16+ monocyte subset with anti-inflammatory phenotype. Experimental and therapeutic medicine. 2020; 19(3): 2243-2251. DOI: https:// doi.org/10.3892/etm.2020.8467.
Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H., et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European heart journal. 2018; 39(2): 119–177. DOI: https://doi.org/10.1093/eurheartj/ehx393.
Davies M.J., D'Alessio D.A., Fradkin J., Kernan W.N., Mathieu C., Mingrone G., et al. Management of hyperglycaemia in type 2 diabetes. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018; 61(12): 2461–2498. DOI: https://doi.org/10.1007/s00125-018-4729-5.
Obokata M., Iso T., Ohyama Y., Sunaga H., Kawaguchi T., Matsui H., et al. Early increase in serum fatty acid binding protein 4 levels in patients with acute myocardial infarction. European heart journal. Acute cardiovascular care. 2018; 7(6): 561–569. DOI: https://doi.org/10.1177/2048872616683635.
Kratochvilova H., Kasperova B.J., Lacinova Z., Lankova I., Trnovska J., Netuka I., et al. CTRP3, a Novel adipokine with anti-inflammatory and cardioprotective properties, in patients with cardiovascular diseases and type 2 diabetes mellitus. Diabetes. 2020; 69: 91-OR. DOI: https://doi.org/10.2337/db20-91-OR.
